The company continues to gain from this system, which in turn bolsters overall performance.In fourth-quarter 2019, da Vinci procedures improved 19% globally compared with the prior-year quarter.The same for earnings stands at $13.23 per share, suggesting growth of 3.7% from the year-ago reported figure.Stocks to ConsiderSome other better-ranked stocks from the broader medical space include Accuray Incorporated ARAY, West Pharmaceutical Services, Inc. WST and DexCom, Inc. DXCM, each currently carrying a Zacks Rank #2 (Buy).